HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • Will Improving Adherence Optimize Medication Use?
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Archives for HEOR Feature

Report Spotlights Marketing During COVID-19

A new report from Reuters Events offers guidance for pharmaceutical industry solutions providers looking for fresh insights into marketing strategies during the COVID-19 pandemic. The report offers agencies a four-step strategy for marketing during the pandemic, and includes perspectives from […]

more info 07/14/2020View Related Articles
Bookmark and Share

ICER Hosting Series on Drug Pricing During a Pandemic

The Institute for Clinical and Economic Review (ICER) is scheduled to host a three-part series focused on drug pricing during a pandemic. The first session, which will discuss cost-recovery pricing, is set for noon EST July 24. Confirmed speakers include: Afton Cissell, JD, Senior Counsel […]

more info 07/13/2020View Related Articles
Bookmark and Share

Report: European Drug Regulatory Network Faces Uncertain, Complex Future

A new strategy produced by European regulators considers future challenges for the European drug regulatory network, The Pink Sheet reports. The plan, per the report, looks to position the regulatory network to endure an uncertain future. To read the report, click here. […]

more info 07/09/2020View Related Articles
Bookmark and Share

ICER Outlines Planned Review of High Cholesterol Treatments

The Institute for Clinical and Economic Review (ICER) in a recently-released document outlines its planned review of high cholesterol treatments. ICER's assessment will include Novartis' inclisiran, Esperion Therepeutics' Nexletol and Nexlizet, according to a press release. Comments on the […]

more info 07/07/2020View Related Articles
Bookmark and Share

Panel Discusses Provider Prospective on Value-Based Care for mBC

A recent panel discussion on AJMC's Peer Exchange discusses how providers identify value-based care opportunities for metastatic breast cancer. The panel features Drs. William Gradishar and Joyce O'Shaughnessy, Bruce Feinberg, Kelli Davis and Steven Peskin. To listen to the discussion on […]

more info 07/03/2020View Related Articles
Bookmark and Share

Evidation Looks to Bolster Platform to Include Virtual Treatment

After generating $45 million in investments, Evidation is looking to expand its virtual research platform to include digital interventions and treatments, FierceBiotech reports. According to the report, the platform already has some 4 million participants in the U.S. "Participation in research […]

more info 07/02/2020View Related Articles
Bookmark and Share

Gilead CEO: Remdesivir Priced ‘Significantly’ Below Value to Society

Gilead CEO Daniel O'Day told STAT he's confident in the company's pricing decision for the COVID-19 drug remdesivir. "We spent a lot of time and considerable care and discussion about how to approach the pricing of this medicine," he said. "At this price it's significantly below the value it […]

more info 07/01/2020View Related Articles
Bookmark and Share

ICER President: Remdesivir Price was ‘Responsible’ Decisions

The Institute for Clinical and Economic Review's president, Steven Pearson, says Gilead's decision to price its COVID-19 treatment remdesivir at $3,120 was a "responsible pricing decision based on the evidence we have today." Gilead also plans to offer some federal programs a discounted price of […]

more info 06/30/2020View Related Articles
Bookmark and Share

Oncologists Grapple with Supply Shortages Amid Pandemic, Survey Finds

A new survey found that one of oncologists' biggest concerns amid the COVID-19 pandemic is supply shortages, Specialty Pharmacy Continuum reports. The survey by the International Society of Oncology Pharmacy Practitioners (ISOPP) suggests oncologists continue to struggle with drug and personal […]

more info 06/29/2020View Related Articles
Bookmark and Share

Cytel Outlines Use of Bayesian Methodologies

A new white paper from Cytel outlines how its statisticians have used Bayesian methodologies in the search for effective COVID-19 treatments. "The sense of urgency incites clinical researchers to invoke innovative trial design approaches to expedite the identification of efficacious interventions […]

more info 06/27/2020View Related Articles
Bookmark and Share

ISPOR Offers Short Courses on Medical Devices, Payment Models

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is offering short courses on medical devices and different payment models for drugs and other products. Below are the two intermediate courses: Market Access & Value Assessment of Medical Devices, 10 a.m. EST […]

more info 06/26/2020View Related Articles
Bookmark and Share

NPC: ‘Ready, aim, fire’ Mentality Detrimental in Health Care

Having a "ready, aim, fire" mentality can prove harmful when sharing health care information, the National Pharmaceutical Council (NPC) writes in a recent blog post. NPC points to the Institute for Clinical and Economic Review's (ICER) report on COVID-19 treatments, calling it "a prime example of […]

more info 06/25/2020View Related Articles
Bookmark and Share

ISPOR-FDA Summit Transitions to Virtual Event

The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) announced that the joint ISPOR-FDA Summit 2020, set for Sept. 29, will be a virtual event this year. ISPOR and the FDA Center for Devices and Radiological Health are hosting the one-day event. "Virtual ISPOR-FDA […]

more info 06/24/2020View Related Articles
Bookmark and Share

Cytel Offers On-Demand Access to Webinar on Synethic, External Control Arms

A new on-demand webinar from Cytel offers insights into synthetic and external control arms in clinical trials. The webinar features Cytel Real-World Evidence Senior Vice President Kristian Thorlund. Cytel also recently published a new scientific primer on using synthetic control arms in place […]

more info 06/23/2020View Related Articles
Bookmark and Share

Kreis: Challenging Price of Costly CF Drug Not ‘Discrimination’

Maurice Kreis, head of the New Hampshire Office of the Consumer Advocate, says challenging the price of Vertex Pharmaceuticals' cystic fibrosis drug is not "discrimination." Kreis, whose 18-year-old daughter has cystic fibrosis, was referring to how some critics responded to ICER's suggestion […]

more info 06/22/2020View Related Articles
Bookmark and Share

ICER to Review Most Significant Drug Price Hikes

The Institute for Clinical and Economic Review (ICER) is set to review whether the most significant drug price increases are evidence-based. ICER on Friday released an updated protocol for the annual assessment. An open input period on the drugs tapped for review began Friday, June 19, and […]

more info 06/20/2020View Related Articles
Bookmark and Share

Analysis Finds Clinical Trial Costs are Actually Modest

A new analysis published in BMJ Open suggests that clinical trial costs for new drugs are generally modest, according to a STAT report. The analysis, which looked at 101 drugs approved by the FDA between 2015 and 2017, found the median cost of clinical trials to be roughly $48 million per […]

more info 06/19/2020View Related Articles
Bookmark and Share

New Definition of HTA

In a letter to the editor published in Value in Health, Brian O'Rourke, Wija Oortwijn and Tara Schuller offer a new definition of health technology assessment (HTA). The authors define HTA as the following: "HTA is a multidisciplinary process that uses explicit methods to determine the value […]

more info 06/18/2020View Related Articles
Bookmark and Share

Report: EMA Considers Big Data Network ‘Priority’

The European Medicines Agency (EMA) says the development of a big data network is a "priority" project, according to a Pink Sheet report. According to the report, the agency's 2019 report offered some insight into plans for a new data network. To read the full report on The Pink Sheet, click […]

more info 06/17/2020View Related Articles
Bookmark and Share

ISPOR Europe 2020 Deadline for Abstract Submissions Nears

The abstract submission deadline for ISPOR's upcoming European meeting is July 8. ISPOR 2020 Europe is set to kick off Nov. 14 in Milan, Italy. "At the start of a new decade in the shadow of a global pandemic, the questioning of fundamental conventions around value, risk, rewards, and the role […]

more info 06/16/2020View Related Articles
Bookmark and Share

Researchers Support Targeted Population Health Interventions to Boost COVID-19 Outcomes

Health care systems should target population health interventions to patients with existing chronic diseases to bolster COVID-19 outcomes, researchers in a recent opinion piece suggest. "The global response has been to treat COVID-19 as a vertical disease rather than addressing the full ecosystem […]

more info 06/14/2020View Related Articles
Bookmark and Share

Where Epidemiologists are Leaning on Kids Returning to School

A recent New York Times Upshot article offers comments from 133 epidemiologists on the matter of children returning to school amid the COVID-19 pandemic. The article expands on a survey by The Times in which it asked more than 500 epidemiologists when they planned to resume 20 common activities. […]

more info 06/14/2020View Related Articles
Bookmark and Share

Article: U.S. Should Scrap Specialty Drug Label

The U.S. should abandon the specialty-drug label for high-cost drugs and follow suit with other countries that categorize drugs by their clinical- and cost-effectiveness, the authors of a recent article published in NEJM write. Categorizing all expensive drugs as being specialty drugs, Huseyin […]

more info 06/13/2020View Related Articles
Bookmark and Share

ICER to CF Community: ‘We Support Actions to Receive Fair Prices’

The Institute for Clinical and Economic Review (ICER) in a letter to the cystic fibrosis community says it supports fair prices that ensure patient access to key drugs. ICER attempted to reassure the community that its position on Trikafta remained one that stresses the need for price […]

more info 06/12/2020View Related Articles
Bookmark and Share

How Can Pharma Best Interact with ICER?

A new report from FirstWord looks at how pharma can best engage with the Institute for Clinical and Economic Review (ICER) as its influence in negotiations continues to increase. The report, "Engaging with ICER: Lessons and Insights for Pharma," includes insight from pharmaceutical industry […]

more info 06/11/2020View Related Articles
Bookmark and Share

Using AI, NLP and Data Visualization with RWE to Generate Insights into Care Gaps: Retrospective Cohort Analysis of Fracture Risk in Patients with Osteopenia and Osteoporosis

Sponsored by Veradigm Real world data (RWD) are being used by an increasingly diverse group of stakeholders. As an example, patient advocacy groups are realizing the value they can offer to their communities by partnering with data analysis companies to explore treatment pathways, health […]

more info 06/10/2020View Related Articles
Bookmark and Share

Report Suggests COVID-19 Could Cost Insurers up to $547 Billion

  A new report from Wakely, commissioned by America's Health Insurance Plans (AHIP), suggests COVID-19 could cost payers between $30 billion and $547 billion through 2021, FierceHealthcare reports. In its report, which is an update to the original report posted in March, Wakely says […]

more info 06/09/2020View Related Articles
Bookmark and Share

Optum: 8 Forces That Will Determine the Future

Optum in a recent perspective offers eight main drivers that will determine the course of health care beyond the COVID-19 pandemic. "The Coronavirus (COVID-19) has upended the entire health care landscape — and the danger and breadth of the pandemic has accelerated change to previously unseen […]

more info 06/08/2020View Related Articles
Bookmark and Share

Houghton St Press Launches New Journal

Houghton St Press recently launched its 10th journal, The Journal of Health Policy and Economics (JOHPEC). The new peer-reviewed journal will focus on health-related works by London School of Economics health policy students. JOHPEC is accepting submissions for its summer issue. To learn […]

more info 06/07/2020View Related Articles
Bookmark and Share

Health Affairs Editor: Institutions Must Use Power to Fight Racism

Health Affairs Editor Alan Weil in a recent blog post says health care institutions must "use their power to fight racism," adding that it is insufficient to only stand against and protest it. Weil's blog post, titled "The Social Determinants of Death," spotlights social determinants of health […]

more info 06/04/2020View Related Articles
Bookmark and Share

  • Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 34
  • Next Page

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Payers: The New Catalysts of Better Health
  • A writer’s role in drug development: a guide to getting started in regulatory medical writing
  • Virtual Medical Conferences: The new normal?
  • How Healthy Are Your Market Access Programs? ​​​​​​​A guide to performing check-ups on pharmaceutical distribution and patient access programs
  • The Overlooked Patient: How payers can identify, engage and treat the vulnerable populations not participating in their own care
  • Unlocking the potential of a Chief Outcomes Officer
  • Pharma’s path for digital health solutions
  • Gartner 2020 Magic Quadrant for Data Science + Machine Learning Platforms
  • How Are Changing Reimbursement Models Affecting Denials?
  • Regulation and Market Climate Force the Issue of CDM Prices
  • The Missing C-Suite Role
  • Patient- or Participant-Generated Registries
  • Multinational Registries: Challenges and Opportunities
  • Managing Missing Data in Patient Registries
  • Biorepositories
  • Increasing Focus on the Patient in Patient Registries
  • DIA DIRECT: Real-World Data to Inform COVID-19 Response: Collaborating in the COVID-19 Evidence Accelerator
  • Demonstrating the Value of Drugs for Rare Diseases – 8 Common Challenges and How to Address Them Before They Arise
  • How to Put AI + Predictive Analytics To Work
  • Insurance Design and Pharmaceutical Innovation
  • Global Biosimilars Pathways and Clinical Development Activity
  • Telemedicine adoption grew in most EU5 markets as COVID mitigation measures took hold
  • Mitigating COVID-19-related healthcare disruption
  • Marketing during COVID-19: A guide for pharma solution providers
  • State of Patient Centricity 2020: Advancing from Patient-first Intentions to True Co-creation
  • Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19
  • Bayesian Methodologies for COVID-19 Drugs, Devices and Biologics
  • Excellence In Payer Engagement: Strategic Outputs From A Roundtable Discussion
  • Evidence Generation and Communication: A Guide to Getting Started in HEOR/Market Access Medical Writing
  • Preparing for ICER assessments: key recommendations for manufacturers

Syndicated Reports

  • Pharmaceutical Payment System Market – Quantitative Analysis, Current and Future Trends, 2020 – 2027
  • The Future of Personalised Medicine: The Role of Simulation and Digital Twins
  • Medical Diagnostics: leveraging new opportunities from AI driven technology
  • Massive Growth in Digital Health Technology Market by Athenahealth, McKesson Corporation, Qualcomm, LifeWatch, AT & T, Cerner Corporation, Philips Healthcare, Cisco Systems
  • Real World Evidence: The Role of Medical Affairs
  • Pharmacy Benefit Management (PBM) – Industry Size 2019, Market Opportunities, Share Analysis up to 2025
  • Democrats and Drug Pricing
  • Global Health Economics & Outcomes Research (HEOR) Services Market Size, Share, Growth, Status and Forecast 2019-2025
  • Global Value-Based Reimbursement Software Market Size, Status and Forecast to 2026
  • Benchmarking Key Account Management Capabilities (2019)
  • The Future of Key Account Management in Pharma
  • Indication-level Pricing: Payer Insights
  • Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
  • Success in Managed Markets: Payer Insights
  • Real World Data and Evidence: Payer Insights
  • KAM Metrics: Measuring Success (2019)
  • Biomarkers and Companion diagnostics: Payer Insights
  • Paying for Digital Health: Payer Insights (2019)
  • Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026
  • Biosimilars: US Payer Insights (2019)
  • Review of Influence: The Institute for Clinical and Economic Review
  • Innovative Drugs: Mapping the Pricing and Reimbursement Landscape
  • Orphan Drugs: European Payer Perspectives
  • Do Payers Really Want Pay-for-Performance?
  • Payer Engagement: Benchmarking Team Structure and Activity
  • Benchmarking Market Access Strategies for High-Cost Drugs and Biologics
  • Blockchain: Transformational Change for Pharma?
  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
  • Paying for Digital Health: Payer Insights
  • Benchmarking Pharma’s MSL Capabilities
HealthEconomics.Com

HealthEconomics.Com

  • Become a Better Writer!
  • HealthEconomics.Com Recognized as Top Influencer at ISPOR International Meeting in Washington DC
  • Will ICER Framework Destroy Progress Against Multiple Myeloma?
  • Celgene Unleashes the Power of Data into Clinical Trial Design
  • How Well is Harvoni Working in the Real World?
  • New CVS and Express Scripts Value Based Plans for Oncology
  • Oversized Cancer Drug Vials Waste $3B Each Year
  • Can More Data Make Providers’ Jobs Easier?
  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Take This Survey for a Chance to Win $200!
  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • ICER Releases Two Draft Reports on Obeticholic Acid
  • What do Patient Advocates Think of New ICER Report?
  • Could a New ICER Report Put Patients at Risk?
  • Contact Us

About

  • International Myeloma Foundation Responds to ICER Report
  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • Doctor Evidence Launches GROWTH Replicator Program
  • Is PCORI Underfunding CER?
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • Will Improving Adherence Optimize Medication Use?
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute